Zanubrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Approved
Selectivity scorecard
KISS
98.24
Gini
0.788
CATDS
0.033
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Zanubrutinib. Strongest target: ERBB4_HER4 at 99.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 99.6% | 0.4% |
| 2 | BMX_ETK | 99.3% | 0.7% |
| 3 | BLK | 99.1% | 0.9% |
| 4 | BTK | 97.4% | 2.6% |
| 5 | TXK | 96.9% | 3.1% |
| 6 | TEC | 95.8% | 4.2% |
| 7 | BRK | 93.4% | 6.6% |
| 8 | MEK2 | 89.9% | 10.1% |
| 9 | FGR | 88.4% | 11.6% |
| 10 | EGFR | 88.2% | 11.8% |
| 11 | LCK | 87.3% | 12.7% |
| 12 | YES_YES1 | 85.0% | 15.0% |
| 13 | ITK | 74.5% | 25.4% |
| 14 | CSK | 64.0% | 36.0% |
| 15 | MEK1 | 54.1% | 45.9% |
| 16 | SRMS | 54.0% | 46.0% |
| 17 | FYN | 50.7% | 49.3% |
| 18 | LYN | 50.3% | 49.7% |
| 19 | FLT3 | 47.8% | 52.2% |
| 20 | ERBB2_HER2 | 47.2% | 52.8% |
Selectivity landscape
Where Zanubrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Zanubrutinib.
Annotations
Sign in to read and post annotations.
Loading…